A Pilot Study of the Safety and Tolerability of Etanercept in Patients with Alcoholic Hepatitis

Menon, K. V. Narayanan; Stadheim, Linda; Kamath, Patrick S.; Wiesner, Russell H.; Gores, Gregory J.; Peine, Craig J.; Shah, Vijay
February 2004
American Journal of Gastroenterology;Feb2004, Vol. 99 Issue 2, p255
Academic Journal
BACKGROUND: Alcoholic hepatitis is a cause of major morbidity and mortality, and effective therapeutic regimens to treat this condition are lacking. Both experimental and clinical evidence indicates that tumor necrosis factor alpha (TNF), and the downstream cytokine interleukin-6 (IL-6), correlate with disease severity and may contribute to the pathogenesis and clinical sequelae of alcoholic hepatitis, thereby implicating a possible role for inhibition of TNF in the treatment of alcoholic hepatitis.OBJECTIVE: The aim of the current study was to assess the safety and tolerability of a p75-soluble TNF receptor:FC fusion protein (etanercept), an agent that binds and neutralizes soluble TNF in patients with alcoholic hepatitis in the form of an open-label pilot trial.METHODS: Etanercept administration was targeted for 2 wk duration in 13 patients with moderate or severe alcoholic hepatitis as assessed by a discriminant function value greater than 15 and/or the presence of spontaneous hepatic encephalopathy.RESULTS: On an intention-to-treat basis, the 30-day survival rate of patients receiving etanercept was 92% (12/13). Adverse events that were encountered included infection, hepatorenal decompensation, and GI bleeding, which required premature discontinuation of etanercept in 23% of patients (3/13).This is the first study to examine TNF inhibition with etanercept in patients with alcoholic hepatitis and the results of this study support the rationale for larger controlled studies to further assess safety and efficacy.


Related Articles

  • Etanercept is Not Harmful.  // Fertility Weekly;1/14/2002, p17 

    Describes the first case of ovulation induction, intrauterine insemnation, normal pregnancy and singleton delivery of a healthy infant following chronic pre-ovulatory tumor necrosis factor-alpha inhibitor therapy for rheumatoid arthritis. Existence of a theoretical risk; Confirmation of a...

  • Peripheral visual field loss following treatment with etanercept. Clifford, L. J.; Rossiter, J. D. // British Journal of Ophthalmology;Jun2004, Vol. 88 Issue 6, p842 

    Etanercept is a relatively new anti-tumour necrosis factor alpha (TNF-alpha) therapy for inflammatory arthritides. Although there may be an association with uveitis, there have been no reports of patients experiencing visual disturbance. Authors present a case of a patient, who developed...

  • Severe Refractory Erythema Nodosum Leprosum Successfully Treated with the Tumor Necrosis Factor Inhibitor Etanercept. Ramien, Michele L.; Wong, Alexander; Keystone, Jay S. // Clinical Infectious Diseases;3/1/2011, Vol. 52 Issue 5, pe133 

    Erythema nodosum leprosum (ENL), or type II reaction, is a common complication of lepromatous leprosy that can cause significant patient debility. First-line therapy includes prednisone and thalidomide, with clofazimine reserved for patients who do not respond to first-line treatment. We present...

  • Psoriasis's changing face. Petrou, IIya // Dermatology Times;Jul2009, Vol. 30 Issue 7, p91 

    The article offers information related to psoriasis, including its history, current treatment and biologics. It mentions that psoriasis is well known in 1841 and its tropical treatment for localized psoriasis can include tar, topical corticosteroids, topical calcipotriene and topical tazarotene....

  • Summary of worldwide pediatric malignancies reported after exposure to etanercept. McCroskery, Peter; Wallace, Carol A.; Lovell, Daniel J.; Stryker, Scott; Chernyukhin, Nataliya; Blosch, Consuelo; Zack, Debra J. // Pediatric Rheumatology;2010, Vol. 8, p18 

    Background: Concerns have been raised about a potential link between the use of TNF inhibitors and development of malignancy in the pediatric population. We examined the worldwide experience of etanercept use in pediatric patients and the occurrence of malignancies as reported from clinical...

  • A case of autoimmune hepatitis exacerbated by the administration of etanercept in the patient with rheumatoid arthritis. Harada, Koji; Akai, Yasuhiro; Koyama, Sachi; Ikenaka, Yasuhide; Saito, Yoshihiko // Clinical Rheumatology;Aug2008, Vol. 27 Issue 8, p1063 

    A 50-year-old woman was admitted for active rheumatoid arthritis (RA). She was found to have RA 1 year prior to this admission. Past history was unremarkable and she had no family history for rheumatic diseases. As nonsteroidal anti-inflammatory drug (NSAID) and methotrexate were not effective,...

  • An Endogenous TNF-α Antagonist Induced by Splice-switching Oligonucleotides Reduces Inflammation in Hepatitis and Arthritis Mouse Models. Graziewicz, Maria A.; Tarrant, Teresa K.; Buckley, Brian; Roberts, Jennifer; Fulton, LeShara; Hansen, Henrik; Ørum, Henrik; Kole, Ryszard; Sazani, Peter // Molecular Therapy;Jul2008, Vol. 16 Issue 7, p1316 

    Tumor necrosis factor-α (TNF-α) is a key mediator of inflammatory diseases, including rheumatoid arthritis (RA), and anti–TNF-α drugs such as etanercept are effective treatments. Splice-switching oligonucleotides (SSOs) are a new class of drugs designed to induce therapeutically...

  • Awakenings. Elkan, Daniel // New Scientist;8/9/2008, Vol. 198 Issue 2668, p32 

    The article reports on the use of the anti-inflammatory drug etanercept to cure Alzheimer's disease (AD). The use of etanercept, a drug more commonly used to treat rheumatoid arthritis, on AD was developed by Edward Tobinick. According to the author, the treatment does not work for everybody,...

  • Study identifies factors linked with better medication response for treatment of juvenile arthritis.  // Biomedical Market Newsletter;11/16/2011, Vol. 21, p375 

    The article focuses on the factors associated with better medication response in the drug etanercept as treatment for patients with juvenile idiopathic arthritis (JIA). It states that the ability to identify patients who respond to etanercept treatment would be an important step to create...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics